Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - PDL BIOPHARMA, INC. | pdli20130228_8k.htm |
| EX-99 - EXHIBIT 99.1 - PDL BIOPHARMA, INC. | pdli20130228_8kex99-1.htm |
| EX-99 - EXHIBIT 99.2 - PDL BIOPHARMA, INC. | pdli20130228_8kex99-2.htm |
Exhibit 99.3
PDL BioPharma, Inc.
Q4 / Year End 2012
March 1, 2013
Following are some of the key points regarding PDL’s fourth quarter 2012 financial and business results.
Net Income
|
● |
Net income for the fourth quarter of 2012 was $49.4 million or $0.34 per diluted share as compared with net income of $38.9 million or $0.24 per diluted share for the same period of 2011. |
|
● |
Net income for full-year 2012 was $211.7 million, or $1.45 per diluted share as compared with net income of $199.4 million in 2011 or $1.15 per diluted share. |
2012 and 2013 Dividends
|
● |
We paid $0.15 per share of common stock, or $21.0 million, on December 14, 2012, to our stockholders of record on December 7, 2012, as part of our regular, quarterly dividend policy for 2012. |
|
● |
In January 2013, PDL announced that its board of directors declared that the regular, quarterly dividends to be paid to its stockholders in 2013 will be $0.15 per share of common stock. The $0.15 dividends will each be paid on March 12, June 12, September 12 and December 12 of 2013 to all stockholders who own shares of PDL on March 5, June 5, September 5 and December 5 of 2013, the record dates for each of the dividend payments, respectively. |
Updates on Approved Royalty Bearing Products
Avastin® (bevacizumab):
|
● |
On January 30, 2013, Roche reported that 2012 worldwide sales increased by 6% over 2011 sales on a constant exchange basis. |
|
o |
In EU, higher sales were driven by the launch in ovarian cancer, and increased market share in lung cancer and breast cancer. |
|
o |
In Japan, higher sales were driven by increased uptake in colorectal cancer, non-small cell lung cancer and metastatic breast cancer. |
|
● |
On November 16, 2012, Genentech/Roche announced that the EU’s CHMP adopted a positive opinion regarding the use of Avastin in second line metastatic colorectal cancer. |
|
o |
A similar application has been granted priority review by the FDA in US. |
|
o |
Avastin is already approved for first line treatment of metastatic colorectal cancer in US and EU. |
|
● |
On November 19, 2012, Genentech/Roche reported additional details from a Phase 3 trial in patients with newly diagnosed glioblastoma that showed that treatment with Avastin plus radiation and chemotherapy increased progression-free-survival by 36% compared to radiation and chemotherapy. |
|
o |
Avastin is already approved for second line treatment of glioblastoma in US and EU. |
|
● |
On February 7, 2013, the National Institutes of Health announced that a trial in patients with recurrent and metastatic cervical cancer comparing Avastin plus two chemotherapies against two chemotherapies met its primary endpoint of improving median overall survival by 3.7 months. |
|
o |
Genentech/Roche said that they are analyzing the data to evaluate next steps. |
Herceptin® (trastuzumab):
|
● |
On January 30, 2013, Roche reported that 2012 worldwide sales increased by 11% over 2011 sales on a constant exchange basis. |
|
o |
Much of the growth was seen in US and emerging markets. |
|
o |
Also contributing to the sales growth was increased HER2 testing and further uptake in HER2+ gastric cancer. |
PDL BioPharma, Inc.
Q4 / Year End 2012
March 1, 2013
Lucentis® (ranibizumab):
|
● |
On January 30, 2013, Roche reported that 2012 US sales decreased by 8% over 2011 sales on a constant exchange basis. |
|
o |
Roche said that it expects further pressure on sales for the treatment of age-related macular degeneration in 2013 partially offset by increased sales for the treatment of diabetic macular edema and stable share for the treatment of retinal vein occlusion. |
|
● |
On January 23, 2013, Novartis reported that 2012 ex-US sales increased by 22% over 2011 sales on a constant exchange basis. |
|
o |
Increased sales growth was driven by new launches for the treatment of diabetic macular edema and retinal vein occlusion. |
Actemra® (tocilizumab):
|
● |
On January 30, 2013, Roche reported that 2012 worldwide sales increased by 33% over 2011 sales on a constant exchange basis. |
|
o |
On October 15, 2012, Genentech/Roche announced that the label had been expanded to include patients who had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). |
|
o |
Subcutaneous formulation filed for approval in US and EU in December 2012. |
Perjeta™ (pertuzumab):
|
● |
On January 30, 2013, Roche reported that 4Q12 demand increased by 53% over 3Q12 demand. |
|
o |
Over 75% of relevant physicians are already prescribing Perjeta. |
Kadcyla™ (TDM-1 or ado-trastuzumab emtansine):
|
● |
On February 22, 2013, Genentech/Roche announced that the FDA had approved the product for second line treatment of HER2+ metastatic breast cancer and first line treatment for those patients who relapse within six months following adjuvant therapy. |
|
o |
A similar application has been accepted for review in EU. |
|
o |
Kadcyla will be available in the US within two weeks. |
|
o |
Pricing is $9,800 per month, significantly higher than many estimates in the financial community. |
Updates on Select Development Stage Potential Royalty Bearing Products
Obinutuzumab:
|
● |
On January 30, 2013, Genentech/Roche announced positive results from Stage 1 of a Phase 3 trial in patients with previously untreated chronic lymphocytic leukemia that showed treatment with obinutuzumab plus chemotherapy significantly reduced the risk of disease worsening or death compared to treatment with chemotherapy. |
|
o |
Stage1 also included a pre-planned progression-free-survival (PFS) futility analysis comparing obinutuzumab plus chemotherapy to Rituxan plus chemotherapy. The goal of the futility analysis was to evaluate the likelihood that the study would meet its pre-specified endpoint criteria during Stage 2 analysis - improved efficacy (PFS) in the direct comparison of obinutuzumab plus chemotherapy to Rituxan plus chemotherapy. |
|
o |
The independent Data and Safety Monitoring Board (DSMB) assessment concluded that Stage 2 of the study should continue until its final analysis. |
PDL BioPharma, Inc.
Q4 / Year End 2012
March 1, 2013
Solanezumab:
|
● |
On August 24, 2012, Lilly announced that both of its Phase 3 trials did not meet the primary endpoints of cognitive and functional benefit. |
|
o |
A pre-specified secondary subgroup analysis of the pooled data from both trials showed that solanezumab slowed the cognitive decline in patients with mild disease but not patients with moderate disease. |
|
● |
On December 12, 2012, Lilly said that it will commence an additional Phase 3 trial in patients with mild Alzheimer’s disease by no later than 3Q2013. |
|
● |
If solanezumab were to receive marketing authorization, PDL would receive a patent royalty of 3% in addition to a 12.5 year know-how royalty of 2% from date of first sale. |
|
● |
On January 18, 2013, the NIH's National Institute of Aging (NIA) announced that it and other federal agencies will fund a three year trial investigating the use of solanezumab in 1,000 patients with abnormal amyloid protein buildup but who are at the pre-symptomatic stage of Alzheimer's disease. |
|
o |
The leading hypothesis explaining Alzheimer's disease is that abnormal amyloid accumulates into clumps on the brain, which clumps secrete toxins causing neuronal damage in brain tissue that eventually results in cognitive deficits. |
|
o |
NIA selected solanezumab after considering a number of anti-amyloid treatments. |
Forward-looking Statements
This document contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new income generating assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.
PDL BioPharma, Inc.
Q4 / Year End 2012
March 1, 2013
|
Royalty Revenue by Product ($ in 000's) * |
||||||||||||||||||||
|
Avastin |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
23,215 | 41,670 | 25,955 | 30,041 | 120,882 | |||||||||||||||
|
2011 |
22,283 | 41,967 | 23,870 | 22,886 | 111,006 | |||||||||||||||
|
2010 |
16,870 | 44,765 | 29,989 | 24,922 | 116,547 | |||||||||||||||
|
2009 |
13,605 | 35,161 | 21,060 | 15,141 | 84,966 | |||||||||||||||
|
2008 |
9,957 | 30,480 | 19,574 | 12,394 | 72,405 | |||||||||||||||
|
2007 |
8,990 | 21,842 | 17,478 | 9,549 | 57,859 | |||||||||||||||
|
2006 |
10,438 | 15,572 | 15,405 | 12,536 | 53,952 | |||||||||||||||
|
Herceptin |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
25,702 | 44,628 | 30,433 | 28,307 | 129,070 | |||||||||||||||
|
2011 |
25,089 | 42,209 | 31,933 | 21,812 | 121,042 | |||||||||||||||
|
2010 |
23,402 | 38,555 | 27,952 | 25,441 | 115,350 | |||||||||||||||
|
2009 |
16,003 | 32,331 | 26,830 | 18,615 | 93,779 | |||||||||||||||
|
2008 |
14,092 | 34,383 | 28,122 | 20,282 | 96,880 | |||||||||||||||
|
2007 |
19,035 | 28,188 | 22,582 | 14,802 | 84,608 | |||||||||||||||
|
2006 |
15,142 | 19,716 | 21,557 | 20,354 | 76,769 | |||||||||||||||
|
Lucentis |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
10,791 | 27,938 | 12,552 | 11,097 | 62,377 | |||||||||||||||
|
2011 |
8,878 | 24,313 | 12,157 | 10,750 | 56,099 | |||||||||||||||
|
2010 |
7,220 | 19,091 | 10,841 | 8,047 | 45,198 | |||||||||||||||
|
2009 |
4,621 | 12,863 | 8,123 | 6,152 | 31,759 | |||||||||||||||
|
2008 |
3,636 | 11,060 | 7,631 | 4,549 | 26,876 | |||||||||||||||
|
2007 |
2,931 | 6,543 | 6,579 | 3,517 | 19,570 | |||||||||||||||
|
2006 |
- | - | 289 | 3,335 | 3,624 | |||||||||||||||
|
Xolair |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
5,447 | 8,609 | 6,504 | 6,145 | 26,705 | |||||||||||||||
|
2011 |
4,590 | 7,621 | 5,916 | 5,823 | 23,949 | |||||||||||||||
|
2010 |
3,723 | 6,386 | 4,980 | 4,652 | 19,741 | |||||||||||||||
|
2009 |
2,665 | 5,082 | 4,085 | 3,722 | 15,553 | |||||||||||||||
|
2008 |
1,488 | 4,866 | 3,569 | 2,927 | 12,850 | |||||||||||||||
|
2007 |
1,684 | 3,942 | 3,332 | 2,184 | 11,142 | |||||||||||||||
|
2006 |
2,263 | 2,969 | 3,041 | 2,495 | 10,768 | |||||||||||||||
|
Perjeta |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
- | - | 58 | 250 | 308 | |||||||||||||||
|
2011 |
- | - | - | - | - | |||||||||||||||
|
2010 |
- | - | - | - | - | |||||||||||||||
|
2009 |
- | - | - | - | - | |||||||||||||||
|
2008 |
- | - | - | - | - | |||||||||||||||
|
2007 |
- | - | - | - | - | |||||||||||||||
|
2006 |
- | - | - | - | - | |||||||||||||||
|
Tysabri |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
11,233 | 12,202 | 11,749 | 12,255 | 47,439 | |||||||||||||||
|
2011 |
9,891 | 10,796 | 11,588 | 11,450 | 43,725 | |||||||||||||||
|
2010 |
8,791 | 8,788 | 8,735 | 9,440 | 35,754 | |||||||||||||||
|
2009 |
6,656 | 7,050 | 7,642 | 8,564 | 29,912 | |||||||||||||||
|
2008 |
3,883 | 5,042 | 5,949 | 6,992 | 21,866 | |||||||||||||||
|
2007 |
839 | 1,611 | 2,084 | 2,836 | 7,370 | |||||||||||||||
|
2006 |
- | - | - | 237 | 237 | |||||||||||||||
|
Actemra |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
1,705 | 2,074 | 2,145 | 2,462 | 8,385 | |||||||||||||||
|
2011 |
913 | 1,136 | 1,401 | 1,460 | 4,910 | |||||||||||||||
|
2010 |
1,587 | 237 | 315 | 688 | 2,827 | |||||||||||||||
|
2009 |
585 | 537 | 909 | 1,197 | 3,228 | |||||||||||||||
|
2008 |
44 | - | 146 | 369 | 559 | |||||||||||||||
|
2007 |
32 | - | - | 17 | 49 | |||||||||||||||
|
2006 |
- | - | - | - | - | |||||||||||||||
|
* As reported to PDL by its licensees | ||||||||||||||||||||
|
Totals may not sum due to rounding |
PDL BioPharma, Inc.
Q4 / Year End 2012
March 1, 2013
Reported Net Sales Revenue by Product ($ in 000's) *
|
Avastin |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
1,502,757 | 1,573,727 | 1,551,327 | 1,662,977 | 6,290,788 | |||||||||||||||
|
2011 |
1,597,461 | 1,582,705 | 1,581,095 | 1,469,994 | 6,231,255 | |||||||||||||||
|
2010 |
1,506,788 | 1,596,892 | 1,594,707 | 1,646,218 | 6,344,605 | |||||||||||||||
|
2009 |
1,345,487 | 1,295,536 | 1,439,730 | 1,514,053 | 5,594,806 | |||||||||||||||
|
2008 |
980,715 | 1,084,930 | 1,180,427 | 1,239,382 | 4,485,454 | |||||||||||||||
|
2007 |
678,068 | 746,587 | 797,013 | 875,084 | 3,096,752 | |||||||||||||||
|
2006 |
439,318 | 516,052 | 570,551 | 592,897 | 2,118,817 | |||||||||||||||
|
Herceptin |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
1,515,255 | 1,625,313 | 1,663,695 | 1,650,495 | 6,454,759 | |||||||||||||||
|
2011 |
1,391,568 | 1,559,975 | 1,642,898 | 1,432,771 | 6,027,211 | |||||||||||||||
|
2010 |
1,270,846 | 1,349,512 | 1,300,934 | 1,409,310 | 5,330,602 | |||||||||||||||
|
2009 |
1,210,268 | 1,133,993 | 1,226,435 | 1,278,626 | 4,849,323 | |||||||||||||||
|
2008 |
1,105,426 | 1,195,215 | 1,211,982 | 1,186,806 | 4,699,428 | |||||||||||||||
|
2007 |
891,761 | 949,556 | 979,602 | 1,015,033 | 3,835,952 | |||||||||||||||
|
2006 |
529,585 | 659,719 | 761,099 | 803,576 | 2,753,979 | |||||||||||||||
|
Lucentis |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
1,079,092 | 1,086,543 | 1,097,541 | 1,109,695 | 4,372,871 | |||||||||||||||
|
2011 |
887,757 | 943,418 | 1,052,809 | 1,075,015 | 3,958,999 | |||||||||||||||
|
2010 |
721,967 | 698,890 | 745,376 | 804,684 | 2,970,917 | |||||||||||||||
|
2009 |
462,103 | 469,736 | 555,296 | 615,212 | 2,102,347 | |||||||||||||||
|
2008 |
363,615 | 393,682 | 460,167 | 454,922 | 1,672,386 | |||||||||||||||
|
2007 |
224,820 | 219,579 | 299,995 | 322,300 | 1,066,695 | |||||||||||||||
|
2006 |
- | - | 10,689 | 157,742 | 168,431 | |||||||||||||||
|
Xolair |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
310,234 | 314,638 | 347,796 | 340,431 | 1,313,100 | |||||||||||||||
|
2011 |
267,754 | 277,642 | 310,874 | 314,911 | 1,171,182 | |||||||||||||||
|
2010 |
228,859 | 225,878 | 251,055 | 263,389 | 969,179 | |||||||||||||||
|
2009 |
184,669 | 181,086 | 211,006 | 219,693 | 796,454 | |||||||||||||||
|
2008 |
137,875 | 169,521 | 177,179 | 183,753 | 668,329 | |||||||||||||||
|
2007 |
129,172 | 130,700 | 144,250 | 147,754 | 551,876 | |||||||||||||||
|
2006 |
95,241 | 99,354 | 112,608 | 118,002 | 425,204 | |||||||||||||||
|
Perjeta |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
- | - | 5,080 | 25,000 | 30,079 | |||||||||||||||
|
2011 |
- | - | - | - | - | |||||||||||||||
|
2010 |
- | - | - | - | - | |||||||||||||||
|
2009 |
- | - | - | - | - | |||||||||||||||
|
2008 |
- | - | - | - | - | |||||||||||||||
|
2007 |
- | - | - | - | - | |||||||||||||||
|
2006 |
- | - | - | - | - | |||||||||||||||
|
Tysabri |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
374,430 | 401,743 | 391,623 | 408,711 | 1,576,508 | |||||||||||||||
|
2011 |
329,696 | 356,876 | 388,758 | 381,618 | 1,456,948 | |||||||||||||||
|
2010 |
293,047 | 287,925 | 293,664 | 316,657 | 1,191,292 | |||||||||||||||
|
2009 |
221,854 | 229,993 | 257,240 | 285,481 | 994,569 | |||||||||||||||
|
2008 |
129,430 | 163,076 | 200,783 | 233,070 | 726,359 | |||||||||||||||
|
2007 |
30,468 | 48,715 | 71,972 | 94,521 | 245,675 | |||||||||||||||
|
2006 |
- | - | - | 7,890 | 7,890 | |||||||||||||||
|
Actemra |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
|||||||||||||||
|
2012 |
56,662 | 66,624 | 71,505 | 82,053 | 276,843 | |||||||||||||||
|
2011 |
30,433 | 35,370 | 46,709 | 48,671 | 161,183 | |||||||||||||||
|
2010 |
52,908 | 5,405 | 10,493 | 22,919 | 91,725 | |||||||||||||||
|
2009 |
19,504 | 17,920 | 30,313 | 39,888 | 107,625 | |||||||||||||||
|
2008 |
1,452 | 1,377 | 5,981 | 12,305 | 21,115 | |||||||||||||||
|
2007 |
- | - | - | 1,137 | 1,137 | |||||||||||||||
|
2006 |
- | - | - | - | - | |||||||||||||||
|
* As reported to PDL by its licensees | |||||
|
Totals may not sum due to rounding |
PDL BioPharma, Inc.
Q4 / Year End 2012
March 1, 2013
Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *
|
Avastin Sales |
2011 - Q3 |
2011 - Q4 |
2012 - Q1 |
2012 - Q2 |
2012 - Q3 |
2012 - Q4 |
||||||||||||||||||
|
US Made & Sold |
688,966 | 684,878 | 652,824 | 724,483 | 679,914 | 710,501 | ||||||||||||||||||
|
US Made & ex-US Sold |
587,975 | 375,830 | 448,037 | 532,979 | 428,976 | 281,905 | ||||||||||||||||||
|
ex-US Made & Sold |
304,155 | 409,286 | 401,896 | 316,265 | 442,437 | 670,572 | ||||||||||||||||||
|
Total |
1,581,095 | 1,469,994 | 1,502,757 | 1,573,727 | 1,551,327 | 1,662,977 | ||||||||||||||||||
|
US Made & Sold |
44 | % | 47 | % | 43 | % | 46 | % | 44 | % | 43 | % | ||||||||||||
|
US Made & ex-US Sold |
37 | % | 26 | % | 30 | % | 34 | % | 28 | % | 17 | % | ||||||||||||
|
ex-US Made & Sold |
19 | % | 28 | % | 27 | % | 20 | % | 29 | % | 40 | % | ||||||||||||
|
Herceptin Sales |
2011 - Q3 |
2011 - Q4 |
2012 - Q1 |
2012 - Q2 |
2012 - Q3 |
2012 - Q4 |
||||||||||||||||||
|
US Made & Sold |
445,395 | 453,168 | 456,920 | 497,109 | 503,612 | 515,790 | ||||||||||||||||||
|
US Made & ex-US Sold |
495,086 | 612,908 | 523,353 | 466,477 | 545,625 | 552,127 | ||||||||||||||||||
|
ex-US Made & Sold |
702,416 | 366,695 | 534,982 | 661,727 | 614,459 | 582,578 | ||||||||||||||||||
|
Total |
1,642,898 | 1,432,771 | 1,515,255 | 1,625,313 | 1,663,695 | 1,650,495 | ||||||||||||||||||
|
US Made & Sold |
27 | % | 32 | % | 30 | % | 31 | % | 30 | % | 31 | % | ||||||||||||
|
US Made & ex-US Sold |
30 | % | 43 | % | 35 | % | 29 | % | 33 | % | 33 | % | ||||||||||||
|
ex-US Made & Sold |
43 | % | 26 | % | 35 | % | 41 | % | 37 | % | 35 | % | ||||||||||||
|
Lucentis Sales |
2011 - Q3 |
2011 - Q4 |
2012 - Q1 |
2012 - Q2 |
2012 - Q3 |
2012 - Q4 |
||||||||||||||||||
|
US Made & Sold |
422,335 | 428,884 | 433,428 | 412,131 | 385,746 | 381,592 | ||||||||||||||||||
|
US Made & ex-US Sold |
630,474 | 646,131 | 645,665 | 674,411 | 711,795 | 728,103 | ||||||||||||||||||
|
ex-US Made & Sold |
- | - | - | - | - | - | ||||||||||||||||||
|
Total |
1,052,809 | 1,075,015 | 1,079,092 | 1,086,543 | 1,097,541 | 1,109,695 | ||||||||||||||||||
|
US Made & Sold |
40 | % | 40 | % | 40 | % | 38 | % | 35 | % | 34 | % | ||||||||||||
|
US Made & ex-US Sold |
60 | % | 60 | % | 60 | % | 62 | % | 65 | % | 66 | % | ||||||||||||
|
ex-US Made & Sold |
0 | % | 0 | % | 0 | % | 0 | % | 0 | % | 0 | % | ||||||||||||
|
Xolair Sales |
2011 - Q3 |
2011 - Q4 |
2012 - Q1 |
2012 - Q2 |
2012 - Q3 |
2012 - Q4 |
||||||||||||||||||
|
US Made & Sold |
184,837 | 188,728 | 185,505 | 193,600 | 211,702 | 210,892 | ||||||||||||||||||
|
US Made & ex-US Sold |
- | - | - | - | - | - | ||||||||||||||||||
|
ex-US Made & Sold |
126,037 | 126,184 | 124,729 | 121,039 | 136,094 | 129,540 | ||||||||||||||||||
|
Total |
310,874 | 314,911 | 310,234 | 314,638 | 347,796 | 340,431 | ||||||||||||||||||
|
US Made & Sold |
59 | % | 60 | % | 60 | % | 62 | % | 61 | % | 62 | % | ||||||||||||
|
US Made & ex-US Sold |
0 | % | 0 | % | 0 | % | 0 | % | 0 | % | 0 | % | ||||||||||||
|
ex-US Made & Sold |
41 | % | 40 | % | 40 | % | 38 | % | 39 | % | 38 | % | ||||||||||||
|
Perjeta Sales |
2011 - Q3 |
2011 - Q4 |
2012 - Q1 |
2012 - Q2 |
2012 - Q3 |
2012 - Q4 |
||||||||||||||||||
|
US Made & Sold |
- | - | - | - | 5,080 | 24,571 | ||||||||||||||||||
|
US Made & ex-US Sold |
- | - | - | - | - | 428 | ||||||||||||||||||
|
ex-US Made & Sold |
- | - | - | - | - | - | ||||||||||||||||||
|
Total |
- | - | - | - | 5,080 | 25,000 | ||||||||||||||||||
|
US Made & Sold |
0 | % | 0 | % | 0 | % | 0 | % | 100 | % | 98 | % | ||||||||||||
|
US Made & ex-US Sold |
0 | % | 0 | % | 0 | % | 0 | % | 0 | % | 2 | % | ||||||||||||
|
ex-US Made & Sold |
0 | % | 0 | % | 0 | % | 0 | % | 0 | % | 0 | % | ||||||||||||
|
Total Sales |
2011 - Q3 |
2011 - Q4 |
2012 - Q1 |
2012 - Q2 |
2012 - Q3 |
2012 - Q4 |
||||||||||||||||||
|
US Made & Sold |
1,741,534 | 1,755,657 | 1,728,678 | 1,827,323 | 1,786,053 | 1,843,345 | ||||||||||||||||||
|
US Made & ex-US Sold |
1,713,535 | 1,634,869 | 1,617,054 | 1,673,867 | 1,686,395 | 1,562,564 | ||||||||||||||||||
|
ex-US Made & Sold |
1,132,608 | 902,165 | 1,061,607 | 1,099,031 | 1,192,990 | 1,382,690 | ||||||||||||||||||
|
Total |
4,587,677 | 4,292,691 | 4,407,339 | 4,600,221 | 4,665,438 | 4,788,598 | ||||||||||||||||||
|
US Made & Sold |
38 | % | 41 | % | 39 | % | 40 | % | 38 | % | 38 | % | ||||||||||||
|
US Made & ex-US Sold |
37 | % | 38 | % | 37 | % | 36 | % | 36 | % | 33 | % | ||||||||||||
|
ex-US Made & Sold |
25 | % | 21 | % | 24 | % | 24 | % | 26 | % | 29 | % | ||||||||||||
|
* As reported to PDL by its licensees | ||||||||||||||||||||||||
|
Totals may not sum due to rounding |